|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI
|
|
2
|
Islami F, Torre LA and Jemal A: Global
trends of lung cancer mortality and smoking prevalence. Transl Lung
Cancer Res. 4:327–338. 2015.PubMed/NCBI
|
|
3
|
Koch M, Gräfenstein L, Karnosky J, Schulz
C and Koller M: Psychosocial burden and quality of life of lung
cancer patients: Results of the EORTC QLQ-C30/QLQ-LC29
questionnaire and hornheide screening instrument. Cancer Manag Res.
13:6191–6197. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lu T, Yang X, Huang Y, Zhao M, Li M, Ma K,
Yin J, Zhan C and Wang Q: Trends in the incidence, treatment, and
survival of patients with lung cancer in the last four decades.
Cancer Manag Res. 11:943–953. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Besse B, Adjei A, Baas P, Meldgaard P,
Nicolson M, Paz-Ares L, Reck M, Smit EF, Syrigos K, Stahel R, et
al: 2nd ESMO consensus conference on lung cancer: Non-small-cell
lung cancer first-line/second and further lines of treatment in
advanced disease. Ann Oncol. 25:1475–1484. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tan WL, Jain A, Takano A, Newell EW, Iyer
NG, Lim WT, Tan EH, Zhai W, Hillmer AM, Tam WL and Tan DSW: Novel
therapeutic targets on the horizon for lung cancer. Lancet Oncol.
17:e347–e362. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Palma D, Visser O, Lagerwaard FJ,
Belderbos J, Slotman BJ and Senan S: Impact of introducing
stereotactic lung radiotherapy for elderly patients with stage I
non-small-cell lung cancer: A population-based time-trend analysis.
J Clin Oncol. 28:5153–5159. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Palma DA and Senan S: Improving outcomes
for high-risk patients with early-stage non-small-cell lung cancer:
Insights from population-based data and the role of stereotactic
ablative radiotherapy. Clin Lung Cancer. 14:1–5. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Potters L, Kavanagh B, Galvin JM, Hevezi
JM, Janjan NA, Larson DA, Mehta MP, Ryu S, Steinberg M, Timmerman
R, et al: American society for therapeutic radiology and oncology
(ASTRO) and American college of radiology (ACR) practice guideline
for the performance of stereotactic body radiation therapy. Int J
Radiat Oncol Biol Phys. 76:326–332. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Timmerman R, Paulus R, Galvin J, Michalski
J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone
D, et al: Stereotactic body radiation therapy for inoperable early
stage lung cancer. JAMA. 303:1070–1076. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Senthi S, Haasbeek CJA, Slotman BJ and
Senan S: Outcomes of stereotactic ablative radiotherapy for central
lung tumours: A systematic review. Radiother Oncol. 106:276–282.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ball D, Mai GT, Vinod S, Babington S,
Ruben J, Kron T, Chesson B, Herschtal A, Vanevski M, Rezo A, et al:
Stereotactic ablative radiotherapy versus standard radiotherapy in
stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): A phase 3,
open-label, randomised controlled trial. Lancet Oncol. 20:494–503.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chang JY, Senan S, Paul MA, Mehran RJ,
Louie AV, Balter P, Groen HJM, McRae SE, Widder J, Feng L, et al:
Stereotactic ablative radiotherapy versus lobectomy for operable
stage I non-small-cell lung cancer: A pooled analysis of two
randomised trials. Lancet Oncol. 16:630–637. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Chang JY, Mehran RJ, Feng L, Verma V, Liao
Z, Welsh JW, Lin SH, O'Reilly MS, Jeter MD, Balter PA, et al:
Stereotactic ablative radiotherapy for operable stage I
non-small-cell lung cancer (revised STARS): Long-term results of a
single-arm, prospective trial with prespecified comparison to
surgery. Lancet Oncol. 22:1448–1457. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Altorki N, Wang X, Damman B, Mentlick J,
Landreneau R, Wigle D, Jones DR, Conti M, Ashrafi AS, Liberman M,
et al: Lobectomy, segmentectomy, or wedge resection for peripheral
clinical T1aN0 non-small cell lung cancer: A post hoc analysis of
CALGB 140503 (Alliance). J Thorac Cardiovasc Surg. 167:338–347.e1.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Raz DJ, Zell JA, Ou S-HI, Gandara DR,
Anton-Culver H and Jablons DM: Natural history of stage I non-small
cell lung cancer: Implications for early detection. Chest.
132:193–199. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Baine MJ, Verma V, Schonewolf CA, Lin C
and Simone CB II: Histology significantly affects recurrence and
survival following SBRT for early stage non-small cell lung cancer.
Lung Cancer. 118:20–26. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Zhang J, Yang F, Li B, Li H, Liu J, Huang
W, Wang D, Yi Y and Wang J: Which is the optimal biologically
effective dose of stereotactic body radiotherapy for Stage I
non-small-cell lung cancer? A meta-analysis. Int J Radiat Oncol
Biol Phys. 81:e305–e316. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Birim O, Kappetein AP and Bogers AJJC:
Charlson comorbidity index as a predictor of long-term outcome
after surgery for nonsmall cell lung cancer. Eur J Cardiothorac
Surg. 28:759–762. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Birim O, Maat APWM, Kappetein AP, van
Meerbeeck JP, Damhuis RAM and Bogers AJJC: Validation of the
Charlson comorbidity index in patients with operated primary
non-small cell lung cancer. Eur J Cardiothorac Surg. 23:30–34.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Charlson ME, Pompei P, Ales KL and
MacKenzie CR: A new method of classifying prognostic comorbidity in
longitudinal studies: Development and validation. J Chronic Dis.
40:373–383. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Edge SB and Compton CC: The American joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification of Malignant Tumours. 8th Edition.
Wiley-Blackwell; Hoboken, NJ, USA: pp. 129–136. 2016
|
|
24
|
Cerfolio RJ, Ojha B, Bryant AS, Raghuveer
V, Mountz JM and Bartolucci AA: The accuracy of integrated PET-CT
compared with dedicated PET alone for the staging of patients with
nonsmall cell lung cancer. Ann Thorac Surg. 78:1017–1023. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Clarke K, Taremi M, Dahele M, Freeman M,
Fung S, Franks K, Bezjak A, Brade A, Cho J, Hope A and Sun A:
Stereotactic body radiotherapy (SBRT) for non-small cell lung
cancer (NSCLC): Is FDG-PET a predictor of outcome? Radiother Oncol.
104:62–66. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Freeman M, Ennis M and Jerzak KJ:
Karnofsky performance status (KPS) ≤60 is strongly associated with
shorter brain-specific progression-free survival among patients
with metastatic breast cancer with brain metastases. Front Oncol.
12:8674622022. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Buccheri G, Ferrigno D and Tamburini M:
Karnofsky and ECOG performance status scoring in lung cancer: A
prospective, longitudinal study of 536 patients from a single
institution. Eur J Cancer. 32A:1135–1141. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Agustí A, Celli BR, Criner GJ, Halpin D,
Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes de Oca
M, et al: Global initiative for chronic obstructive lung disease
2023 report: GOLD executive summary. Am J Respir Crit Care Med.
207:819–837. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mirza S, Clay RD, Koslow MA and Scanlon
PD: COPD guidelines: A review of the 2018 GOLD report. Mayo Clin
Proc. 93:1488–1502. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Charlson ME, Carrozzino D, Guidi J and
Patierno C: Charlson comorbidity index: A critical review of
clinimetric properties. Psychother Psychosom. 91:8–35. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fowler JF: The linear-quadratic formula
and progress in fractionated radiotherapy. Br J Radiol. 62:679–694.
1989. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Klement RJ, Sonke JJ, Allgäuer M,
Andratschke N, Appold S, Belderbos J, Belka C, Blanck O, Dieckmann
K, Eich HT, et al: Correlating dose variables with local tumor
control in stereotactic body radiation therapy for early-stage
non-small cell lung cancer: A modeling study on 1500 individual
treatments. Int J Radiat Oncol Biol Phys. 107:579–586. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang Z: Variable selection with stepwise
and best subset approaches. Ann Transl Med. 4:1362016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Henschke CI, Yip R, Sun Q, Li P, Kaufman
A, Samstein R, Connery C, Kohman L, Lee P, Tannous H, et al:
Prospective cohort study to compare long-term lung cancer-specific
and all-cause survival of clinical early stage (T1a-b; ≤20 mm)
NSCLC treated by stereotactic body radiation therapy and surgery. J
Thorac Oncol. 19:476–490. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Fan S, Zhang Q, Chen J, Chen G, Zhu J, Li
T, Xiao H, Du S, Zeng Z and He J: Comparison of long-term outcomes
of stereotactic body radiotherapy (SBRT) via Helical tomotherapy
for early-stage lung cancer with or without pathological proof.
Radiat Oncol. 18:492023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Speicher PJ and D'Amico TA: Weighing the
relative importance of short-term versus long-term outcomes when
comparing surgery versus stereotactic body radiation therapy (SBRT)
for early-stage non-small cell lung cancer. J Thorac Dis. 10 (Suppl
17):S2022–S2024. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Arnett ALH, Mou B, Owen D, Park SS, Nelson
K, Hallemeier CL, Sio T, Garces YI, Olivier KR and Merrell KW:
Long-term clinical outcomes and safety profile of SBRT for
centrally located NSCLC. Adv Radiat Oncol. 4:422–428. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Guckenberger M, Allgäuer M, Appold S,
Dieckmann K, Ernst I, Ganswindt U, Holy R, Nestle U,
Nevinny-Stickel M, Semrau S, et al: Safety and efficacy of
stereotactic body radiotherapy for stage 1 non-small-cell lung
cancer in routine clinical practice: A patterns-of-care and outcome
analysis. J Thorac Oncol. 8:1050–1058. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jimenez-Jimenez E, Marti-Laosa MM,
Nieto-Guerrero JM, Perez ME, Gómez M, Lozano E and Sabater S:
Biologically effective dose (BED) value lower than 120 Gy improve
outcomes in lung SBRT. Clin Transl Oncol. 26:1203–1208. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kreinbrink P, Blumenfeld P, Tolekidis G,
Sen N, Sher D and Marwaha G: Lung stereotactic body radiation
therapy (SBRT) for early-stage non-small cell lung cancer in the
very elderly (≥80 years old): Extremely safe and effective. J
Geriatr Oncol. 8:351–355. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Pop DD, Hopîrtean C, Coşer F, Dan F, Zah
T, Fekete Z, Chiş A, Tufăscu G, Udrea A and Mihai A: Implementation
of advanced radiotherapy techniques: Stereotactic body radiotherapy
(SBRT) for oligometastatic patients with lung metastasis-a single
institution experience. Med Pharm Rep. 95:410–417. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Guo Y, Zhu Y, Zhang R, Yang S, Kepka L,
Viani GA, Milano MT, Sio TT, Sun X, Wu H, et al: Five-year
follow-up after stereotactic body radiotherapy for medically
inoperable early-stage non-small cell lung cancer: A multicenter
study. Transl Lung Cancer Res. 12:1293–1302. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Onishi H, Shioyama Y, Matsumoto Y, Matsuo
Y, Miyakawa A, Yamashita H, Matsushita H, Aoki M, Nihei K, Kimura
T, et al: Real-world results of stereotactic body radiotherapy for
399 medically operable patients with stage I histology-proven
non-small cell lung cancer. Cancers (Basel). 15:43822023.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Snider M, Salama JK and Boyer M: Survival
and recurrence rates following SBRT or surgery in medically
operable stage I NSCLC. Lung Cancer. 197:1079622024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Wong OY, Yau V, Kang J, Glick D, Lindsay
P, Le LW, Sun A, Bezjak A, Cho BCJ, Hope A and Giuliani M: Survival
impact of cardiac dose following lung stereotactic body
radiotherapy. Clin Lung Cancer. 19:e241–e246. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Baker S, Sharma A, Peric R, Heemsbergen WD
and Nuyttens JJ: Prediction of early mortality following
stereotactic body radiotherapy for peripheral early-stage lung
cancer. Acta Oncol. 58:237–242. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Eriguchi T, Takeda A, Sanuki N, Tsurugai
Y, Aoki Y, Oku Y, Hara Y, Akiba T and Shigematsu N: Stereotactic
body radiotherapy for operable early-stage non-small cell lung
cancer. Lung Cancer. 109:62–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ganti AK, Siedlik E, Marr AS, Loberiza FR
Jr and Kessinger A: Predictive ability of Charlson comorbidity
index on outcomes from lung cancer. Am J Clin Oncol. 34:593–596.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wilkie JR, Lipson R, Johnson MC, Williams
C, Moghanaki D, Elliott D, Owen D, Atluri N, Jolly S and Chapman
CH: Use and outcomes of SBRT for early stage NSCLC without
pathologic confirmation in the veterans health care administration.
Adv Radiat Oncol. 6:1007072021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Moraes FY, Abreu CECV, Siqueira GSM,
Haddad CK, Degrande FAM, Hopman WM, Neves-Junior WFP, Gadia R and
Carvalho HA: Applying PET-CT for predicting the efficacy of SBRT to
inoperable early-stage lung adenocarcinoma: A Brazilian
case-series. Lancet Reg Health Am. 11:1002412022.PubMed/NCBI
|
|
51
|
Mahasittiwat P, Yuan S, Xie C, Ritter T,
Cao Y, Ten Haken RK and Kong FMS: Metabolic tumor volume on PET
reduced more than gross tumor volume on CT during radiotherapy in
patients with non-small cell lung cancer treated with 3DCRT or
SBRT. J Radiat Oncol. 2:191–202. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Chirindel A, Adebahr S, Schuster D,
Schimek-Jasch T, Schanne DH, Nemer U, Mix M, Meyer P, Grosu AL,
Brunner T and Nestle U: Impact of 4D-(18)FDG-PET/CT imaging on
target volume delineation in SBRT patients with central versus
peripheral lung tumors. Multi-reader comparative study. Radiother
Oncol. 115:335–341. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Hoopes DJ, Tann M, Fletcher JW, Forquer
JA, Lin PF, Lo SS, Timmerman RD and McGarry RC: FDG-PET and
stereotactic body radiotherapy (SBRT) for stage I non-small-cell
lung cancer. Lung Cancer. 56:229–234. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Chen K, Hou L, Chen M, Li S, Shi Y, Raynor
WY and Yang H: Predicting the efficacy of SBRT for lung cancer with
18F-FDG PET/CT radiogenomics. Life (Basel).
13:8842023.PubMed/NCBI
|
|
55
|
Thor M, Fitzgerald K, Apte A, Oh JH, Iyer
A, Odiase O, Nadeem S, Yorke ED, Chaft J, Wu AJ, et al: Exploring
published and novel pre-treatment CT and PET radiomics to stratify
risk of progression among early-stage non-small cell lung cancer
patients treated with stereotactic radiation. Radiother Oncol.
190:1099832024. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yu X, He L, Wang Y, Dong Y, Song Y, Yuan
Z, Yan Z and Wang W: A deep learning approach for automatic tumor
delineation in stereotactic radiotherapy for non-small cell lung
cancer using diagnostic PET-CT and planning CT. Front Oncol.
13:12354612023. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Yu L, Zhang Z, Yi H, Wang J, Li J, Wang X,
Bai H, Ge H, Zheng X, Ni J, et al: A PET/CT radiomics model for
predicting distant metastasis in early-stage non-small cell lung
cancer patients treated with stereotactic body radiotherapy: A
multicentric study. Radiat Oncol. 19:102024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Tyran M, Charrier N, Darreon J, Madroszyk
A, Tallet A and Salem N: Early PET-CT after stereotactic
radiotherapy for stage 1 non-small cell lung carcinoma is
predictive of local control. In Vivo. 32:121–124. 2018.PubMed/NCBI
|
|
59
|
Borm KJ, Oechsner M, Schiller K, Peeken
JC, Dapper H, Münch S, Kroll L, Combs SE and Duma MN: Prognostische
Faktoren bei der stereotaktischen Strahlentherapie von
Lungenmetastasen. Strahlenther Onkol. 194:886–893. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Retif P, Verrecchia-Ramos E, Saleh M,
Djibo Sidikou A, Letellier R, Al Salah A, Pfletschinger E, Taesch
F, Ben-Mahmoud S and Michel X: On the use of 4D-PET/CT for the safe
SBRT re-irradiation of central lung recurrence within
radiation-induced fibrosis: A clinical case. J Clin Med.
14:40152025. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Kessel KA, Grosser RCE, Kraus KM, Hoffmann
H, Oechsner M and Combs SE: Stereotactic body radiotherapy (SBRT)
in patients with lung metastases-prognostic factors and long-term
survival using patient self-reported outcome (PRO). BMC Cancer.
20:4422020. View Article : Google Scholar : PubMed/NCBI
|
